Gumokimab vs Roconkibart

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-17A · full Psoriasis pipeline

Gumokimab

Marketed by Akeso

Phase 3 in Psoriasismonoclonal antibody
Partial signal

NCT06066125 · Phase 3 · completed

The trial was properly randomized, quadruple-blinded, and placebo-controlled with over 350 participants and used hard, regulator-accepted clinical endpoints (PASI75 and sPGA 0/1). However, the only externally available result reports the gumokimab arm's response rate without the placebo arm's rate or any statistical test, so it isn't possible to confirm the pre-specified comparison was statistically significant, which keeps this well-designed trial at a moderate grade rather than strong.

Result from the sponsor's press release or a wire copy of it; no peer-reviewed publication or posted registry results were found.

Reported efficacy

The percentage of subjects who achieved at least 75% reduction in psoriasis area and severity index(PASI) score from baseline (PASI 75) and the percentage of subjects who achieved static physician global assessment(sPGA) 0/1 at week 12.: PASI 75 response at Week 12: 94.6% with gumokimab; PASI 100: 47.7% (unclear)

Result source: NCT06066125

Roconkibart

Developed by Shanghai Junshi Bioscience and partners

Phase 3 in Psoriasismonoclonal antibody
Reliable signal

NCT05975268 · Phase 3 · completed

The trial randomized participants to JS005 150mg, 300mg, or placebo with full blinding of participants, care providers, investigators, and outcomes assessors, in a reasonably large phase 3 population of 747 patients. The primary endpoints -- PASI 90 and sPGA 0/1, both standard hard clinical measures of psoriasis severity -- were reported as met with statistically significant improvement over placebo, satisfying the design and result standards for strong evidence.

Result from the sponsor's press release or a wire copy of it; no peer-reviewed publication or posted registry results were found.

Reported efficacy

Change in PASI 90 (From week 0 to week 12); Change in sPGA (From week 0 to week 12): Both co-primary endpoints and key secondary endpoints showed statistically significant and clinically meaningful improvements (met)

Result source: NCT05975268

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGumokimabRoconkibart
PASI 75—Not posted · NCT06066125—Not posted · NCT05975268
PASI 90—Not posted · NCT06066125—Not posted · NCT05975268
PASI 100—Not posted · NCT06066125—Not posted · NCT05975268
sPGA 0/1—Not posted · NCT06066125—Not posted · NCT05975268
DLQI, change—Not posted · NCT06066125—Not posted · NCT05975268

PASI 75

Gumokimab
—Not posted · NCT06066125
Roconkibart
—Not posted · NCT05975268

PASI 90

Gumokimab
—Not posted · NCT06066125
Roconkibart
—Not posted · NCT05975268

PASI 100

Gumokimab
—Not posted · NCT06066125
Roconkibart
—Not posted · NCT05975268

sPGA 0/1

Gumokimab
—Not posted · NCT06066125
Roconkibart
—Not posted · NCT05975268

DLQI, change

Gumokimab
—Not posted · NCT06066125
Roconkibart
—Not posted · NCT05975268
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Gumokimab
PASI 75 response at Week 12: 94.6% with gumokimab; PASI 100: 47.7% NCT06066125 · Phase 3 · design grade: moderate · publication or press release
Roconkibart
Both co-primary endpoints and key secondary endpoints showed statistically significant and clinically meaningful improvements NCT05975268 · Phase 3 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gumokimab's landscape · Roconkibart's landscape